The Merck & Co Inc (NYQ:MRK) share price is currently trading at $88.5. But given that there is still a lot of uncertainty about the health of the wider economy, the question now is what the future holds for it... To try and predic...
MRK — Merck & Co Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedLarge CapSuper Stock
- $233.43bn
- $256.37bn
- $48.70bn
- 98
- 51
- 98
- 94
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.77 | ||
| PEG Ratio (f) | 2.96 | ||
| EPS Growth (f) | 4.51% | ||
| Dividend Yield (f) | 3.12% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.8 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 18.55 | ||
| Price to Sales | 4.39 | ||
| EV to EBITDA | 13.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.46% | ||
| Return on Equity | 41.02% | ||
| Operating Margin | 28.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 40,122 | 42,294 | 39,121 | 41,518 | 48,704 | 57,909.94 | 56,589.09 | 4.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -34.06 | +2.5 | -4.1 | +18.55 | +44.92 | +7.78 | -0.04 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for MRK
In this article we will quickly re-cap the broker forecasts for Merck & Co Inc (NYQ:MRK). The Merck & Co Inc share price has risen by 7.78% over the past month and it’s currently trading at 85.03. For investors considering whet...
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that these stocks are hard to find - but there are signs that Merck & Co Inc N...
The Merck & Co Inc (NYQ:MRK) share price has risen by 6.66% over the past month and it’s currently trading at 82.9. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will c...
Given widespread disruption and uncertainty in the stock market, it is more important than ever to find high quality stocks for your portfolio. That means safe, profitable companies with strong balance sheets. We all like the idea of i...
Profile Summary
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.
Directors
- Kenneth Frazier CHM (66)
- Robert Davis PRE (54)
- Caroline Litchfield CFO
- Dean Li CEX (58)
- Steven Mizell CHO (60)
- Jennifer Zachary EVP (43)
- Sanat Chattopadhyay EVP (61)
- Richard DeLuca EVP (58)
- Julie Gerberding EVP (65)
- Michael Klobuchar EVP
- Rita Karachun SVF (57)
- Michael Fleming SVP (62)
- Cristal Downing OTH
- Thomas Glocer LED (61)
- Mary Coe IND (54)
- Pamela Craig IND (64)
- Risa Lavizzo-Mourey IND (66)
- Stephen Mayo IND (59)
- Paul Rothman IND (63)
- Patricia Russo IND (69)
- Christine Seidman IND (68)
- Inge Thulin IND (67)
- Kathy Warden IND (49)
- Peter Wendell IND (70)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- July 28th, 1970
- Public Since
- June 15th, 1946
- No. of Shareholders
- 99,932
- No. of Employees
- 68,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 2,528,805,025
- Address
- 2000 Galloping Hill Rd, KENILWORTH, 07033-1310
- Web
- http://www.merck.com/
- Phone
- +1 9087404000
- Auditors
- PricewaterhouseCoopers LLP
Latest News for MRK
Upcoming Events for MRK
Merck & Co Inc at ASCO Annual Meeting
Dividend For MRK.BA - 0.1380 USD
Dividend For MRCK34.SA - 0.4149 BRL
Dividend For MRK.N - 0.6900 USD
Q2 2022 Merck & Co Inc Earnings Call
Q2 2022 Merck & Co Inc Earnings Release
Q3 2022 Merck & Co Inc Earnings Call
Q3 2022 Merck & Co Inc Earnings Release
Similar to MRK
Abbvie
New York Stock Exchange
Amneal Pharmaceuticals
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
FAQ
What is the Merck & Co share price?
As of Today at 13:14 UTC, shares in Merck & Co are trading at $93.75. This share price information is delayed by 15 minutes.
How has the Merck & Co share price performed this year?
Shares in Merck & Co last closed at $93.75 and the price had moved by +26.86% over the past 365 days. In terms of relative price strength the Merck & Co share price has outperformed the S&P500 Index by +33.79% over the past year.
What are the analyst and broker recommendations for Merck & Co?
The overall consensus recommendation for Merck & Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Merck & Co dividend yield?
The Merck & Co dividend yield is 2.86% based on the trailing twelve month period.
Does Merck & Co pay a dividend?
Last year, Merck & Co paid a total dividend of $2.68, and it currently has a trailing dividend yield of 2.86%. We do not have any data on when Merck & Co is to next pay dividends.
When does Merck & Co next pay dividends?
We do not have data on when Merck & Co is to next pay dividends. The historic dividend yield on Merck & Co shares is currently 2.86%.
How do I buy Merck & Co shares?
To buy shares in Merck & Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Merck & Co?
As of the previous close price of $93.75, shares in Merck & Co had a market capitalisation of $233.43bn.
Where are Merck & Co shares listed?
Here are the trading details for Merck & Co:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: MRK
What kind of share is Merck & Co?
Based on an overall assessment of its quality, value and momentum Merck & Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Merck & Co share price forecast for 2022?
The analyst consensus target price for shares in Merck & Co is $98.05. That is 4.58% above the last closing price of $93.75.
Analysts covering Merck & Co currently have a consensus Earnings Per Share (EPS) forecast of $7.34 for the next financial year.
What is the trend in the Merck & Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Merck & Co. Over the past six months, its share price has outperformed the S&P500 Index by +38.57%.
As of the last closing price of $93.75, shares in Merck & Co were trading +16.88% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Merck & Co PE Ratio?
The Merck & Co PE ratio based on its reported earnings over the past 12 months is 12.77. The shares last closed at $93.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Merck & Co?
Merck & Co's management team is headed by:
- Kenneth Frazier - CHM
- Robert Davis - PRE
- Caroline Litchfield - CFO
- Dean Li - CEX
- Steven Mizell - CHO
- Jennifer Zachary - EVP
- Sanat Chattopadhyay - EVP
- Richard DeLuca - EVP
- Julie Gerberding - EVP
- Michael Klobuchar - EVP
- Rita Karachun - SVF
- Michael Fleming - SVP
- Cristal Downing - OTH
- Thomas Glocer - LED
- Mary Coe - IND
- Pamela Craig - IND
- Risa Lavizzo-Mourey - IND
- Stephen Mayo - IND
- Paul Rothman - IND
- Patricia Russo - IND
- Christine Seidman - IND
- Inge Thulin - IND
- Kathy Warden - IND
- Peter Wendell - IND